Cosmetic cross-reference Noindex: medium evidence

1562-00-1

CAS 1562-00-1

1562-00-1 (CAS 1562-00-1) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
1562-00-1
CAS Number
1562-00-1
UNII
3R36J71C17
InChIKey
LADXKQRVAFSPTR-UHFFFAOYSA-M
ChEMBL ID
CHEMBL172191
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
SODIUM ISETHIONATE
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE NLM RxNorm 1 name row

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
SODIUM ISETHIONATE 1364895 SU MTHSPL
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 1562-00-1 used for in pharmaceutical contexts?

1562-00-1 (CAS 1562-00-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 1562-00-1?

No adverse-event association or SIDER side-effect rows are rendered for 1562-00-1 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 1562-00-1 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Isethionate with EU status "permitted".

What clinical phase is 1562-00-1 in?

No phase 1-4 clinical development badge is rendered for 1562-00-1 because the matched compound identifier rows do not contain a max-phase value.